Shrilla Banerjee, MD, FRCP, consultant cardiologist, Surrey and Sussex Healthcare NHS Trust, shares what politicians and clinical trialists can do to help mitigate cardiovascular health disparities.
Shrilla Banerjee, MD, FRCP, consultant cardiologist, Surrey and Sussex Healthcare NHS Trust, describes the social determinants of health (SDOH) that she sees contributing to cardiovascular health disparities in the United Kingdom and what politicians and clinical trialists can do to help mitigate these issues.
Transcript
What are some SDOH that further contribute to cardiovascular health disparities, and what strategies might mitigate their impact on health outcomes?
There are some changes that need to be implemented by politicians. We need to advocate for our patients and lobby politicians to improve living conditions, minimum wage, and the expectation of access to food for school children. It's something that doesn't strike me on a regular basis, because it's not something I'm exposed to, but we have children in schools in the UK who don't eat a proper meal apart from when they go to school.
So, in fact, if we gave [food] access to all school children, it wouldn't be a huge cost but it would improve the quality of life and the lived experience of children from minority populations and from more deprived populations—it's not only minority populations. And it would improve their health care and then their well-being as they go into adulthood, because if you have poor health care nutrition in childhood, it often leads to poor health outcomes as an adult as well.
So there's lots of things we can think about on an institutional level, but on a personal level, obviously addressing your own bias. We need to make sure that our patients who have more economic challenges are encouraged to enroll in clinical trials and be supportive in that way as well.
We perhaps need to make a quota in research. We're suggesting that now for women. Women are often 20% or 30% of clinical trial participants when they're 50%, 52% of the population. So why isn't it 50/50? Certain conditions impact women at a later age, so if there's an age cutoff, you can understand that there may be less women in the age group being randomized. But actually it's not difficult to find more mixed populations, and I think we need to encourage that. If you encourage trialists to enroll more people of color, then I think we'll get more relevant data.
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More
As AI Utilization Advances in Health Care, Experts at ATS 2024 Share Insights
May 20th 2024Fatima Rodriguez, MD, MPH, from Stanford University, and Matthew DeCamp, MD, PhD, from the University of Colorado, joined Michael Howell, MD, MPH, of Google, on the stage at ATS 2024 to discuss artificial intelligence (AI) in health care.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More